CDX-301 clinical trials
Also written CDX-301.
A product of flt3 ligand protein; its studies count on that page too.
How each study uses CDX-301 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CDX-301 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CDX-301
- 5
Studies by the year they started
9 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 6
Celldex Therapeutics (3) · Dana-Farber Cancer Institute (1) · Montefiore Medical Center (1) · Parker Institute for Cancer Immunotherapy (1) · Joshua Brody (1) · University of Texas Southwestern Medical Center (1) · Weill Medical College of Cornell University (1)
Often tested with
Tested in the same studies.
Poly ICLC (3) · NeoVax (1) · Bempegaldesleukin (1) · DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151 (1) · CDX-1140 (1) · Pembrolizumab (1) · Glembatumumab vedotin (1) · Varlilumab (1)
Related medicines
As reviewed, each with the page that says it.
- A brand or code of flt3 ligand protein
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test CDX-301.
- Dec 2026Converting HR+ Breast Cancer Into an Individualized VaccinePhase 2 · Weill Medical College of Cornell University
Studies
Open first, then newest update. How each study uses CDX-301 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerRecruitingPhase 1University of Texas Southwestern Medical CenterNCT05029999Written as CDX-301
- Converting HR+ Breast Cancer Into an Individualized VaccineRecruitingPhase 2Weill Medical College of Cornell UniversityNCT03804944Written as CDX-301
- FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung CancerCompletedPhase 2Montefiore Medical CenterNCT02839265Written as FLT3 Ligand Therapy (CDX-301)
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT04930783Written as CDX-301
- Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsCompletedPhase 1Parker Institute for Cancer ImmunotherapyNCT03835533Written as CDX-301 (Cohort B and C)
- In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose RadiotherapyCompletedPhase 1/2Joshua BrodyNCT01976585Written as rhuFlt3L/CDX-301
- A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedPhase 2Celldex TherapeuticsNCT02302339Written as glembatumumab vedotin and CDX-301
- A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy VolunteersCompletedPhase 1Celldex TherapeuticsNCT01465139Written as CDX-301
- A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedPhase 2Celldex TherapeuticsNCT02200380Written as CDX-301
Given beside what is tested · 3 — CDX-301 is usual care or a partner of the new treatment
- The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.Active, not recruitingPhase 1Ashutosh Kumar TewariNCT05010200Written as CDX-301
- Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer PatientsTerminatedPhase 2Washington University School of MedicineNCT04536077Written as CDX-301
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedPhase 1Celldex TherapeuticsNCT03329950Written as CDX-301